Net Revenue. AtheroGenics shall pay Emory the following running royalties on Net Revenue: (a) [*] of the Net Revenue for Licensed Products utilizing Inventions claimed in any Valid Claim of Licensed Patents in Subgroup (i) Sold in the Licensed Territory; or (b) [*] of the Net Revenue for Licensed Products utilizing Inventions claimed in any Valid Claim of Licensed Patents in Subgroup (ii) or Subgroup (iii) Sold in the Licensed Territory. (c) In the event that a Licensed Product utilizes Inventions claimed by Valid Claims contained in more than one Licensed Patent subgroup, AtheroGenics shall pay the higher of the applicable running royalty rate, but in no case shall pay Emory or its assigns more than [*] of the Net Selling Price for any Licensed Product.
Appears in 2 contracts
Sources: License Agreement (Atherogenics Inc), License Agreement (Atherogenics Inc)